Argos Therapeutics (ARGS) Misses Q2 EPS by 5c
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Argos Therapeutics (NASDAQ: ARGS) reported Q2 EPS of ($0.48), $0.05 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $488.64 thousand versus the consensus estimate of $200 thousand.
For earnings history and earnings-related data on Argos Therapeutics (ARGS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barrick Gold (ABX) Tops Q3 EPS by 4c
- Videocon d2h Limited (VDTH) Reports Q4 EPS of INR0.32
- Agnico Eagle Mines (AEM) Tops Q3 EPS by 6c